127 related articles for article (PubMed ID: 12039880)
21. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
[TBL] [Abstract][Full Text] [Related]
22. In vitro development of resistance to newer fluoroquinolones in Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin.
Mayer S; Boos M; Köhrer K; Fluit AC; Schmitz FJ
Eur J Clin Microbiol Infect Dis; 2001 Apr; 20(4):288-91. PubMed ID: 11399024
[No Abstract] [Full Text] [Related]
23. Contribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae.
Kishii R; Takei M; Fukuda H; Hayashi K; Hosaka M
Antimicrob Agents Chemother; 2003 Jan; 47(1):77-81. PubMed ID: 12499172
[TBL] [Abstract][Full Text] [Related]
24. Increasing genetic relatedness of ciprofloxacin-resistant Streptococcus pneumoniae isolated in Canada from 1997 to 2005.
Nichol KA; Adam HJ; Karlowsky JA; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2008 Mar; 52(3):1190-4. PubMed ID: 18180349
[TBL] [Abstract][Full Text] [Related]
25. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
[TBL] [Abstract][Full Text] [Related]
26. Relative potential for selection of quinolone-resistance-determining-region mutations in Streptococcus pneumoniae by gemifloxacin, gatifloxacin and moxifloxacin.
De Azavedo JC; Duncan CL; Kilburn L; Downar J; Kong B; Lad S; Low DE; Bast DJ
J Chemother; 2006 Aug; 18(4):373-8. PubMed ID: 17024792
[TBL] [Abstract][Full Text] [Related]
27. Fluoroquinolone-resistant Streptococcus pneumoniae strains occur frequently in elderly patients in Japan.
Yokota S; Sato K; Kuwahara O; Habadera S; Tsukamoto N; Ohuchi H; Akizawa H; Himi T; Fujii N
Antimicrob Agents Chemother; 2002 Oct; 46(10):3311-5. PubMed ID: 12234869
[TBL] [Abstract][Full Text] [Related]
28. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
Pan XS; Fisher LM
J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
[TBL] [Abstract][Full Text] [Related]
29. Antibacterial activity of a DNA topoisomerase I inhibitor versus fluoroquinolones in Streptococcus pneumoniae.
Valenzuela MV; Domenech M; Mateos-Martínez P; González-Camacho F; de la Campa AG; García MT
PLoS One; 2020; 15(11):e0241780. PubMed ID: 33141832
[TBL] [Abstract][Full Text] [Related]
30. Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniae.
Johnson CN; Briles DE; Benjamin WH; Hollingshead SK; Waites KB
Emerg Infect Dis; 2005 Jun; 11(6):814-20. PubMed ID: 15963274
[TBL] [Abstract][Full Text] [Related]
31. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
Korzheva N; Davies TA; Goldschmidt R
Antimicrob Agents Chemother; 2005 Jun; 49(6):2479-86. PubMed ID: 15917550
[TBL] [Abstract][Full Text] [Related]
32. Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in target specificity.
Morris JE; Pan XS; Fisher LM
Antimicrob Agents Chemother; 2002 Feb; 46(2):582-5. PubMed ID: 11796384
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae.
Richardson DC; Bast D; McGeer A; Low DE
Antimicrob Agents Chemother; 2001 Jun; 45(6):1911-4. PubMed ID: 11353652
[TBL] [Abstract][Full Text] [Related]
34. Quinolone resistance mechanisms in pneumococci.
Eliopoulos GM
Clin Infect Dis; 2004 May; 38 Suppl 4():S350-6. PubMed ID: 15127369
[TBL] [Abstract][Full Text] [Related]
35. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
[TBL] [Abstract][Full Text] [Related]
36. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.
Gillespie SH; Voelker LL; Ambler JE; Traini C; Dickens A
Microb Drug Resist; 2003; 9(1):17-24. PubMed ID: 12705679
[TBL] [Abstract][Full Text] [Related]
37. Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits.
Etienne M; Croisier D; Charles PE; Lequeu C; Piroth L; Portier H; Drlica K; Chavanet P
J Infect Dis; 2004 Oct; 190(8):1472-5. PubMed ID: 15378440
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of melting curve analysis for screening the most prevalent mutations in topoisomerase genes from Streptococcus pneumoniae.
Melano RG; Higgins R; Seah C; Drews SJ
J Clin Microbiol; 2008 Jan; 46(1):396-7; author reply 397. PubMed ID: 18180371
[No Abstract] [Full Text] [Related]
39. ATP-bound conformation of topoisomerase IV: a possible target for quinolones in Streptococcus pneumoniae.
Sifaoui F; Lamour V; Varon E; Moras D; Gutmann L
J Bacteriol; 2003 Oct; 185(20):6137-46. PubMed ID: 14526026
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms and spread of fluoroquinolone resistance in Streptococcus pneumoniae.
Varon E; Gutmann L
Res Microbiol; 2000; 151(6):471-3. PubMed ID: 10961461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
